Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach
暂无分享,去创建一个
Moisés Blanco-Calvo | Angélica Figueroa | Federico Garrido | Angélica Figueroa | M. Blanco-Calvo | A. Concha | F. Garrido | M. Valladares-Ayerbes | Ángel Concha | Manuel Valladares-Ayerbes
[1] R. Labianca,et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[3] K. Michels,et al. Epigenetic epidemiology of cancer. , 2014, Biochemical and biophysical research communications.
[4] Martin A Nowak,et al. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers , 2014, Proceedings of the National Academy of Sciences.
[5] Melanie A. Huntley,et al. Recurrent R-spondin fusions in colon cancer , 2012, Nature.
[6] S. Hanash,et al. Mining the plasma proteome for cancer biomarkers , 2008, Nature.
[7] F. Bosch,et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.
[8] J. Barrett,et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Renzo Boldorini,et al. Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer , 2011, Clinical Cancer Research.
[10] R. Gillies,et al. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.
[11] Sabine Tejpar,et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] I. Nagtegaal,et al. Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.
[13] A. Bardelli,et al. Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer , 2009, Journal of the National Cancer Institute.
[14] S. Tavazoie,et al. Extracellular Metabolic Energetics Can Promote Cancer Progression , 2015, Cell.
[15] P. Stern,et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.
[16] Parantu K. Shah,et al. canEvolve: A Web Portal for Integrative Oncogenomics , 2013, PloS one.
[17] A. G. de Herreros,et al. Functional Heterogeneity of Cancer-Associated Fibroblasts from Human Colon Tumors Shows Specific Prognostic Gene Expression Signature , 2013, Clinical Cancer Research.
[18] Sabine Tejpar,et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. , 2011, The Lancet. Oncology.
[19] J. Pagès,et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Ken Kato,et al. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection , 2014, Cancer science.
[21] Sabine Tejpar,et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Georg Krupitza,et al. Initial steps of metastasis: Cell invasion and endothelial transmigration , 2011, Mutation research.
[23] Daniel J Sargent,et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.
[24] M. Kloor,et al. Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer , 2015, The American journal of surgical pathology.
[25] Prahlad T. Ram,et al. Cancer Systems Biology: a peek into the future of patient care? , 2014, Nature Reviews Clinical Oncology.
[26] F. Clavel-Chapelon,et al. Dietary Fibre Intake and Risks of Cancers of the Colon and Rectum in the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2012, PloS one.
[27] R. Houlston,et al. Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Gregory J Goodall,et al. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. , 2013, Neoplasia.
[29] S. Friend,et al. Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. , 2014 .
[30] Bruno Landi,et al. Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.
[31] Florian Markowetz,et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions , 2013, Nature Medicine.
[32] A. Frigessi,et al. Principles and methods of integrative genomic analyses in cancer , 2014, Nature Reviews Cancer.
[33] Pradeep S Rajendran,et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors , 2011, Nature Biotechnology.
[34] B. Uzzan,et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. , 2009, European journal of cancer.
[35] Mark J. Ratain,et al. Tumour heterogeneity in the clinic , 2013, Nature.
[36] G. Botti,et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] M. Tzardi,et al. KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer , 2014, PloS one.
[38] C. Swanton. Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.
[39] K. Polyak,et al. Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.
[40] T. Yeatman,et al. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer , 2011, Gut.
[41] F. Marincola,et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.
[42] A. Carrato,et al. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study , 2012, PloS one.
[43] P. Delvenne,et al. Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies , 2014, Hepatology.
[44] C. Bokemeyer,et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. , 2012, European journal of cancer.
[45] Kebin Liu,et al. Epigenetics and Colorectal Cancer Pathogenesis , 2013, Cancers.
[46] C. Sander,et al. MLH1‐silenced and non‐silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes , 2013, The Journal of pathology.
[47] Mira Ayadi,et al. Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.
[48] V. Mootha,et al. Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation , 2012, Science.
[49] Hong Ding,et al. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis , 2011, Molecular Biology Reports.
[50] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[51] H. Lehrach,et al. Somatic Mutation Profiles of MSI and MSS Colorectal Cancer Identified by Whole Exome Next Generation Sequencing and Bioinformatics Analysis , 2010, PloS one.
[52] D. Sargent,et al. Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications , 2012, Clinical Cancer Research.
[53] Céline Lefebvre,et al. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. , 2015, European journal of cancer.
[54] M. Disis,et al. TNM staging in colorectal cancer: T is for T cell and M is for memory. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] F. Bazzoli,et al. Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention , 2013, International journal of molecular sciences.
[56] M. Bertagnolli,et al. Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.
[57] J. Herman,et al. CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[58] Javier Sastre,et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior , 2012, BMC Cancer.
[59] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[60] Zlatko Trajanoski,et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[62] Xi-shan Wang,et al. EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis , 2013, PloS one.
[63] Lewis C Cantley,et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.
[64] S. Veronese,et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[66] M. Ychou,et al. Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib , 2013 .
[67] J. Lamb,et al. A Comprehensive Characterization of Genome-Wide Copy Number Aberrations in Colorectal Cancer Reveals Novel Oncogenes and Patterns of Alterations , 2012, PloS one.
[68] Shuji Ogino,et al. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine , 2012, Expert review of molecular diagnostics.
[69] Alexander Meissner,et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease , 2013, Modern Pathology.
[70] L. V. van't Veer,et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] R. Schilsky,et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] Sabine Tejpar,et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] P. Stern,et al. Natural history of HLA expression during tumour development. , 1993, Immunology today.
[74] William M. Grady,et al. Epigenetics and colorectal cancer , 2011, Nature Reviews Gastroenterology &Hepatology.
[75] F. Garrido,et al. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy , 2010, International journal of cancer.
[76] Louis Vermeulen,et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment , 2010, Nature Cell Biology.
[77] G. Orphanides,et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines , 2012, BMC Medical Genomics.
[78] N. McGranahan,et al. The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.
[79] E. Nice,et al. Proteomics, genomics and transcriptomics: their emerging roles in the discovery and validation of colorectal cancer biomarkers , 2014, Expert review of proteomics.
[80] Zlatko Trajanoski,et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] R. Salazar,et al. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[82] F. Clavel-Chapelon,et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition , 2011, Gut.
[83] M. Wiese,et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[84] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[85] A. Concha,et al. Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity , 2011, Cancer Immunology, Immunotherapy.
[86] F. Clavel-Chapelon,et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study , 2010, BMJ : British Medical Journal.
[87] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[88] Andreas Schlicker,et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition , 2013, International journal of cancer.
[89] A. Bardelli,et al. Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.
[90] Jing Yang,et al. Epithelial–mesenchymal plasticity in carcinoma metastasis , 2013, Genes & development.
[91] D. Kerr,et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] I. Nagtegaal,et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients , 2011, British Journal of Cancer.
[93] Charles J. Vaske,et al. Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing , 2014, Proceedings of the National Academy of Sciences.
[94] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[95] K. Hemminki,et al. Consensus Pathways Implicated in Prognosis of Colorectal Cancer Identified Through Systematic Enrichment Analysis of Gene Expression Profiling Studies , 2011, PloS one.
[96] Corbin E. Meacham,et al. Tumour heterogeneity and cancer cell plasticity , 2013, Nature.
[97] Jin-Ling Tang,et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases , 2015, Scientific Reports.
[98] E. Riboli,et al. Adult weight change and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. , 2013, European journal of cancer.
[99] Sabine Tejpar,et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer , 2013, The Journal of pathology.
[100] Deficient mismatch repair system in patients with sporadic advanced colorectal cancer , 2009, British Journal of Cancer.
[101] C. Compton,et al. Characterization of sporadic colon cancer by patterns of genomic instability. , 2003, Cancer research.
[102] R. Sanz-Pamplona,et al. Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information , 2014, Molecular oncology.
[103] M. Leitzmann,et al. Television viewing and time spent sedentary in relation to cancer risk: a meta-analysis. , 2014, Journal of the National Cancer Institute.
[104] Vladimir Vacic,et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions , 2014, Genome Biology.
[105] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[106] Y. Ohkura,et al. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS , 2014, Cancer Chemotherapy and Pharmacology.
[107] C. Compton,et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] J. L. Tang,et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[109] G. Calin,et al. Clinical relevance of circulating cell-free microRNAs in cancer , 2014, Nature Reviews Clinical Oncology.
[110] Steven J. M. Jones,et al. Meta-analysis of Colorectal Cancer Gene Expression Profiling Studies Identifies Consistently Reported Candidate Biomarkers , 2008, Cancer Epidemiology Biomarkers & Prevention.
[111] R. Labianca,et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. , 2011, Journal of the National Cancer Institute.
[112] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[113] A. Viale,et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] Baorui Liu,et al. Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy , 2013, PloS one.
[115] Carlos Caldas,et al. The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.
[116] Sridhar Ramaswamy,et al. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.
[117] Reiko Nishihara,et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. , 2013, Journal of the National Cancer Institute.
[118] D. Spiegelman,et al. Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803 , 2011, Clinical Cancer Research.
[119] C. Cano,et al. Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape , 2012, Cancer Immunology, Immunotherapy.